Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Study finds unexpected new drug target for acute myeloid leukemia

A study has found an unexpected new drug target for acute myeloid leukemia (AML) that could open new avenues to develop effective treatments against this potentially lethal disease.

27 Nov 2017

High levels of natural immune suppressor in leukemia patients linked to poor survival

Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.

27 Nov 2017

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.

25 Oct 2017

Powering up fat cells could help acute myeloid leukemia patients

Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.

16 Oct 2017

Newly discovered compound causes cancer cell death, whilst sparing healthy cells

Researchers have discovered a compound that can trigger cancer cells to self-destruct, without causing any damage to healthy cells.

10 Oct 2017

New treatment approach makes cancer cells commit suicide while sparing healthy cells

Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells.

9 Oct 2017

New research uncovers how blood cancer 'steals' parts of bone marrow cells to thrive

New research published today uncovers how the blood cancer 'steals' parts of surrounding healthy bone marrow cells to thrive, in work that could help form new approaches to cancer treatment in the future.

5 Oct 2017

Trial identifies genetic fault that affects treatment response in leukemia patients

A genetic fault has been identified in people with an aggressive type of leukemia that can significantly affect how they respond to treatment.

27 Sep 2017

Modified blood thinner may be first promising method to prevent repercussions after TBI

A chemically modified version of the common blood thinner heparin may be the first promising method of preventing the harmful cascade of destruction to brain tissue that commonly follows traumatic brain injury (TBI), according to new research findings.

13 Sep 2017

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).

1 Sep 2017

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

1 Sep 2017

Spot Leukaemia campaign launched to reduce delays in diagnosis

A UK leukemia charity, Leukaemia CARE, has launched the Spot Leukaemia campaign to raise awareness of the signs and symptoms of leukemia after a survey revealed that leukemia diagnoses are commonly delayed due to poor understanding.

1 Sep 2017

New research program receives DKK 100 million in funding from Novo Nordisk Foundation

The newly established research program, 'Program for Translational Hematology', has just received DKK 100 million in funding from the Novo Nordisk Foundation.

From Novo Nordisk 24 Aug 2017

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.

3 Aug 2017

$New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod$

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.

2 Aug 2017

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen's University in Canada to advance the preclinical development of ERYTECH's eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.

12 Jul 2017

Acute Myeloid Leukemia News and Research

Further Reading

Study finds unexpected new drug target for acute myeloid leukemia

High levels of natural immune suppressor in leukemia patients linked to poor survival

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Powering up fat cells could help acute myeloid leukemia patients

Newly discovered compound causes cancer cell death, whilst sparing healthy cells

New treatment approach makes cancer cells commit suicide while sparing healthy cells

New research uncovers how blood cancer 'steals' parts of bone marrow cells to thrive

Trial identifies genetic fault that affects treatment response in leukemia patients

Modified blood thinner may be first promising method to prevent repercussions after TBI

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Spot Leukaemia campaign launched to reduce delays in diagnosis

New research program receives DKK 100 million in funding from Novo Nordisk Foundation

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

Prolonged use of cancer inhibitors can lead to severe cardiovascular problems

Researchers trace origins of AML relapse to rare therapy-resistant stem cells

PNNL-OHSU scientists part of NCI effort to study about role of proteins in cancer biology

Researchers discover how mutations in protein network drive high-risk leukemias

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News